Platform capitalisms and platform cultures.

This article argues for a pluralization of the "platform capitalism" framework, suggesting we should think instead in terms of "platform capitalisms." This pluralization opens the way to a better account of how platforms work in different geocultural contexts, with our focus being on China, India and Japan. The article first outlines several roles the state has taken on in mediating platform capitalisms.

Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium.

Aim: To evaluate the efficacy of 25Gy/5# prophylactic pelvic nodal irradiation for regional control during stereotactic radiotherapy (SBRT) for high risk prostate cancer.

Methods: The multinational XXXX consortium database of patients treated with curative-intent prostate SBRT for high risk prostate cancer was queried for prophylactic radiotherapy 25Gy/5# to the pelvic lymph nodes. Details of Phoenix-defined biochemical failure, and location of recurrence (local, regional, or distant) were extracted.

Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.

It has been shown that magnetic resonance imaging (MRI) guidance versus computed tomography (CT) guidance for aggressive margin-reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces acute toxicity, but the longer-term benefits are unknown. We performed a secondary analysis of MIRAGE, a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer, to determine whether AMR with MRI guidance significantly reduced 2-yr physician-scored or patient-reported toxic effects in comparison to CT guidance. The cumulative incidence of 2-yr physician-scored toxicity, defined as grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxic effects according to Common Terminology Criteria for Adverse Events v4.

CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease.

Introduction: Sickle cell disease is ameliorated and perhaps can be 'cured' if enough fetal hemoglobin is present in most erythrocytes. Hydroxyurea, which increases fetal hemoglobin levels, is widely available and effective, especially in children. Nevertheless, only cell-based gene therapy can achieve a 'curative' fetal hemoglobin threshold.